Tirzepatide vs semaglutide: how do they actually compare? Tirzepatide (Mounjaro, Zepbound) activates both GLP-1 and GIP receptors and produces roughly 15-22% average weight loss in trials, while semaglutide (Ozempic, Wegovy) activates GLP-1 receptors only and produces roughly 10-15% average weight loss.

Wegovy and Zepbound are both approved for chronic weight management, but Zepbound has shown greater average weight loss in head-to-head data and carries an additional approval for obstructive sleep apnea that Wegovy does not.

Saxenda and Wegovy are both approved for chronic weight management, but they contain different active ingredients, liraglutide and semaglutide, with Wegovy's once-weekly dosing and stronger trial results making it the more commonly prescribed of the two.

Ozempic and Mounjaro are both approved for type 2 diabetes, but they contain different active ingredients, semaglutide and tirzepatide, with Mounjaro's dual mechanism showing greater average weight loss in head-to-head trial data.

Trulicity and Ozempic are both once-weekly GLP-1 medications for type 2 diabetes, but they contain different active ingredients, and real-world data suggests Ozempic tends to produce more weight loss and fewer GI side effects than Trulicity.

Head-to-head trial data shows tirzepatide produces greater average weight loss than semaglutide, driven by its dual GLP-1/GIP mechanism, though semaglutide has a longer track record and broader cardiovascular data.